Clinical Trials Logo

Filter by:
NCT ID: NCT05675462 Recruiting - Clinical trials for Hepatocellular Carcinoma

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab plus lenvatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma.

NCT ID: NCT05675254 Completed - Clinical trials for Epilepsy in Children

The Prevalence and Risk Factors of Coagulopathy in Pediatric Epilepsy Surgery Patients

Start date: December 1, 2022
Phase:
Study type: Observational

The hematologic consequences of novel Anti-seizure medications (ASMs) are rarely reported. Whether coagulation dysfunctions increase the risk of peri-operative bleeding remains controversial. The research is performed to investigated the incidence and risk factors of preoperative coagulation dysfunction in children undergoing surgery for epilepsy and their impact on surgery.

NCT ID: NCT05675202 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

Material Balance Study of TQ-B3525

Start date: January 2023
Phase: Phase 1
Study type: Interventional

A clinical study to investigate the absorption, metabolism and excretion of [14C] TQ-B3525 in Chinese adult male healthy subjects, aiming to quantitatively analyze the total radioactivity in the excreta of male healthy subjects after oral administration of [14C] TQ-B3525, obtain the data of human radioactive excretion rate and main drainage routes, investigate the distribution in whole blood and plasma, the distribution in plasma and the pharmacokinetics of total radioactivity in plasma, and identify the main metabolites, To determine the main biotransformation pathway and obtain the pharmacokinetic parameters of TQ-B3525 and its metabolites in plasma.

NCT ID: NCT05675111 Completed - Clinical trials for Immune Checkpoint Inhibitor

Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs)

Start date: June 1, 2018
Phase:
Study type: Observational

Immune checkpoint inhibitor (ICI) includes agents that block cytotoxic T-cell-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1). Since the FDA-approval of the CTLA-4 inhibitor ipilimumab in 2011, ICI drugs have emerged as a powerful new tool in the treatment for several advanced cancers. Now indications for ICI have expanded dramatically due to their efficacy and include a wide array of cancer types. However, the administration of ICI, whereas, carry the risk of developing immune-related adverse events (irAEs) and may lead to serious and even fatal events. Endocrine dysfunctions are among the most common irAEs that have been reported in clinical trials with ICI, including thyroid dysfunction, hypopituitarism, primary adrenal insufficiency (PAI) and insulin-deficient diabetes (ICI-DM). However, it is difficult to acquire a complete picture of irAEs from randomized controlled trials (RCTs) due to limitations in the study design and realistic practicalities.

NCT ID: NCT05675072 Recruiting - Clinical trials for Mild to Moderate COVID-19

Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19

Start date: January 4, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This study is a double-blind,randomized,placebo-controlled study to evaluate the efficacy and safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease 2019(COVID-19). A total of about 1336 subjects are planned to be enrolled. The subjects will be randomized in a 1:1 ratio to FB2001 group or placebo group while both receiving standard of care treatment.

NCT ID: NCT05674812 Recruiting - Clinical trials for Extubation Succeeded

Extubation Guided by Bedside Ultrasound

Start date: December 1, 2022
Phase:
Study type: Observational [Patient Registry]

Prolonged mechanical ventilation is likely to lead to respiratory complications, such as pneumonia, pulmonary edema, atelectasis, pulmonary barotrauma, acute respiratory distress syndrome, etc. The duration of mechanical ventilation after major abdominal surgery in elderly patients was longer, the lung function reserve decreased significantly, and the incidence of postoperative lung complications was as high as 53.1%. Therefore, it is of great clinical significance and social value to accurately grasp the ventilator withdrawal time of elderly patients after surgery and reduce ventilator-related lung injury. In recent years, pulmonary ultrasound has been more and more applied to the lung function assessment of critically ill patients in intensive care unit, while the study of early postoperative extubation guided by bedside lung ultrasound in critically ill patients remains to be explored. Combined with previous work and related literature, our research group planned to conduct a multi-center prospective clinical trial to evaluate the recovery of lung function in elderly patients by using lung ultrasound score (LUS), diaphragm mobility (DD) combined with oxygenation index (OI), and to guide elderly patients undergoing gastrointestinal surgery to perform early extubation in PACU, so as to reduce postoperative ventilators associated lung injury in elderly patients. The application of ERAS concept in abdominal operation of the elderly in this project can effectively reduce the occurrence of postoperative pulmonary complications, accelerate postoperative recovery and rehabilitation of patients, and shorten the length of hospital stay, which has important clinical and social value.

NCT ID: NCT05674539 Recruiting - Clinical trials for Allogeneic Hematopoietic Stem Cell Transplantation

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Start date: December 28, 2022
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare outcomes of two reduced intensity conditioning (RIC) regimens (fludarabine plus busulfan and fludarabine plus melphalan) in allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients. The main questions it aims to answer are: - The safety of two reduced intensity conditioning (RIC) regimens (fludarabine plus busulfan and fludarabine plus melphalan) in allogeneic hematopoietic stem cell transplantation for adult AML/MDS patients with HCT-CI≥3 or aged ≥55 years. - The efficacy of two reduced intensity conditioning (RIC) regimens (fludarabine plus busulfan and fludarabine plus melphalan) in allogeneic hematopoietic stem cell transplantation for adult AML/MDS patients with HCT-CI≥3 or aged ≥55 years. Participants will be randomized to one of two reduced intensity conditioning (RIC) regimens (fludarabine plus busulfan and fludarabine plus melphalan)

NCT ID: NCT05674448 Terminated - Clinical trials for Chronic Hepatitis B and Hepatitis D Co-infection

A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection

Start date: August 11, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label phase IIa study of HH-003 to evaluate its antiviral activity and safety in subjects with chronic hepatitis B and hepatitis D co-infection. HH-003 is a human monoclonal antibody targeting the pre-S1 domain of the HBV large envelope protein. It blocks engagement of preS1 with sodium taurocholate co-transporting polypeptide (NTCP), the cellular receptor for HBV/HDV.

NCT ID: NCT05674305 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

Start date: January 1, 2022
Phase: Phase 3
Study type: Interventional

The goal of this multicenter randomized non-inferior study is to compare radiotherapy alone versus concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma patients whose EBV DNA drop to undetectable level after one cycle neoadjuvant chemotherapy using GP regimen. The main question it aims to answer is: the omission of concurrent chemotherapy is safe in the relatively good prognostic patients identified by the response of EBV DNA. Participants will be randomized to either radiotherapy alone or the standard treatment concurrent chemoradiotherapy if their EBV DNA decrease to undetectable level post first cycle of neoadjuvant chemotherapy and don't rebound in the second and third cycle.

NCT ID: NCT05674214 Completed - Clinical trials for Twin; Pregnancy, Affecting Fetus or Newborn

Birth Weight-discordance in Twins Pregnancy: a Multicenter Retrospective Study

Start date: September 10, 2020
Phase:
Study type: Observational

The rate of twin pregnancies in China has increased by 50 percent over the past decade and now stands at about 3 percent. This is significantly higher than the European and American countries. There are significant differences in birth weight of some newborns, that is, birth weight-discordance in twin pregnancies (BWDT). BWDT was significantly associated with fetal death, preterm birth, neonatal death, and neonatal complications. Existing studies mainly focus on the perinatal outcomes of mothers and infants with BWDT, or are reported from small samples in developed countries. The investigators are aware of the need to further explore the occurrence of birth weight inconsistency and adverse neonatal outcomes in China with a large sample. Through retrospective study design, the investigators will collect clinical data of live twin births at multiple study sites, investigate the incidence of BWDT, and analyze its adverse outcomes.